MARKET

EWTX

EWTX

Edgewise Therapeutics, Inc.
NASDAQ
30.66
-0.34
-1.10%
Pre Market: 30.74 +0.08 +0.26% 06:20 02/12 EST
OPEN
31.09
PREV CLOSE
31.00
HIGH
31.11
LOW
29.30
VOLUME
80
TURNOVER
0
52 WEEK HIGH
31.26
52 WEEK LOW
10.60
MARKET CAP
3.25B
P/E (TTM)
-19.4407
1D
5D
1M
3M
1Y
5Y
1D
Why Edgewise Therapeutics Stock Crushed the Market on Monday
The Motley Fool · 2d ago
Piper Sandler Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)
TipRanks · 2d ago
Weekly Report: what happened at EWTX last week (0202-0206)?
Weekly Report · 3d ago
Edgewise Therapeutics to Present at Guggenheim Emerging Outlook Biotech Summit
Reuters · 6d ago
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
PR Newswire · 6d ago
Edgewise Therapeutics Grants Stock Options to New Employees Under Inducement Plan
Reuters · 02/02 13:02
EDGEWISE THERAPEUTICS REPORTS INDUCEMENT GRANTS AS PERMITTED BY THE NASDAQ LISTING RULES
Reuters · 02/02 13:00
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire · 02/02 13:00
More
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

Webull offers Edgewise Therapeutics Inc stock information, including NASDAQ: EWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EWTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EWTX stock methods without spending real money on the virtual paper trading platform.